跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 91 条关于
“CRF1”
全部
91
临床试验
60
药物
17
机构
0
资讯
14
去年
HMNC Brain Health and Spruce Biosciences Launch Phase 2 Trial for Precision Depression Treatment
去年
Neurocrine Biosciences Initiates Phase 1 Trial for Long-Acting CAH Treatment NBIP-01435
2年前
FDA Grants Breakthrough Therapy Designation to Crinecerfont for Congenital Adrenal Hyperplasia
去年
CRENESSITY Shows Consistent Efficacy Across Pediatric CAH Subgroups While Reducing Glucocorticoid Doses
去年
FDA Grants Priority Review to Crinecerfont for Congenital Adrenal Hyperplasia
去年
Neurocrine Biosciences Advances CAH Treatment Portfolio with Long-Acting Injectable Therapy
去年
FDA Sets PDUFA Date for Neffy Nasal Spray and Approves Crinecerfont for CAH Treatment
去年
Crinecerfont Shows Promise in Pediatric Congenital Adrenal Hyperplasia Across All Patient Subgroups
去年
Neurocrine Biosciences' Crenessity Receives FDA Approval for Congenital Adrenal Hyperplasia
4个月前
Two-Year CRENESSITY Data Shows Sustained Benefits in Pediatric and Adult CAH Patients
第 1 页,共 2 页
上一页
下一页